Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...
المؤلفون الرئيسيون: | Preiss, D, Tobert, JA, Hovingh, GK, Reith, C |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Elsevier
2020
|
مواد مشابهة
-
Lipid-modifying agents, from statins to PCSK9 inhibitors
حسب: Preiss, D, وآخرون
منشور في: (2020) -
LDL Cholesterol, Statins And PCSK 9 Inhibitors
حسب: Sanjiv Gupta
منشور في: (2015-09-01) -
United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
حسب: Caleyachetty, R, وآخرون
منشور في: (2021) -
PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
حسب: K. O. Shnaider, وآخرون
منشور في: (2023-12-01) -
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
حسب: Konstantinos Koskinas, وآخرون
منشور في: (2016-07-01)